相关实验视频
Updated: May 27, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
262
肥胖及其治疗:朝着新的方法
Bérénice Segrestin1, Blandine Gatta Cherifi2
1F-CRIN - FORCE (French Obesity Research Centre of Excellence), CRNH, CARMEN lab INSERM U1060/University of Lyon/INRA U1235, Lyon1 University, Lyon, France; Endocrinology-Diabetes-Nutrition Department, hospices civils de Lyon, Lyon, France.
Annales d'endocrinologie
|February 17, 2025
概括
肥胖需要一个新的定义超越BMI,专注于其复杂的病理生理学和并发症. 个性化治疗,包括新药疗法和生活方式改变,是有效的肥胖管理的关键.
科学领域:
- 内分泌学和新陈代谢学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前使用身体质量指数 (BMI) 的肥胖定义缺乏敏感性.
- 过多的脂肪呈现出机械,代谢和心理方面的并发症.
- 法国卫生局 (2022) 提出了一种以病理生理学为中心的肥胖的定义.
研究的目的:
- 突出需要一个超越BMI的全面肥胖定义.
- 讨论过度脂肪的病理生理学决定因素和并发症.
- 探索针对肥胖管理的个性化治疗策略.
主要方法:
- 肥胖的表型化病理生理学决定因素和并发症.
- 评估饮食行为,能量消耗和情绪性饮食.
- 审查当前和正在发展的治疗干预措施,包括药物治疗.
主要成果:
- 过多的肥胖与高血压和心脏衰竭风险增加有关,通过心肌重塑和腹功能障碍.
- -葡萄糖共运输体2 (SGLT2) 抑制剂在管理与肥胖有关的心血管并发症方面显示出潜在的相关性.
- 目前正在开发Myostatin/activin A途径抑制剂,以在减肥期间保持瘦体质量.
结论:
- 个性化,病理生理驱动的方法对于有效的肥胖治疗至关重要.
- 新型药物治疗,包括SGLT2抑制剂和肌静素通路抑制剂,提供了有前途的途径.
- 终身生活方式干预仍然是改善生活质量和减轻肥胖风险的核心.
相关概念视频
Diabetes: Management and Pharmacotherapy
229
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
229
Obesity
366
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
366
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Hormonal Regulation
43.1K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.1K
Binge Eating Disorders
46
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
46
Oral Hypoglycemic Agents: Biguanides and Glitazones
158
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
158

